Donna Przepiorka,Chia-Wen Ko,Albert Deisseroth,Carolyn L Yancey,Reyes Candau-Chacon,Haw-Jyh Chiu,Brenda J Gehrke,Candace Gomez-Broughton,Robert C Kane,Susan Kirshner,Nitin Mehrotra,Tiffany K Ricks,Deborah Schmiel,Pengfei Song,Ping Zhao,Qing Zhou,Ann T Farrell,Richard Pazdur

Abstract:On December 3, 2014, the FDA granted accelerated approval of blinatumomab (Blincyto; Amgen, Inc.) for treatment of Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL). Blinatumomab is a recombinant murine protein that acts as a bispecific CD19-directed CD3 T-cell engager. The basis for the approval was a single-arm trial with 185 evaluable adults with R/R ALL. The complete remission (CR) rate was 32% [95% confidence interval (CI), 26%-40%], and the median duration of response was 6.7 months. A minimal residual disease response was achieved by 31% (95% CI, 25%-39%) of all patients. Cytokine release syndrome and neurologic events were serious toxicities that occurred. Other common (>20%) adverse reactions were pyrexia, headache, edema, febrile neutropenia, nausea, tremor, and rash. Neutropenia, thrombocytopenia, and elevated transaminases were the most common (>10%) laboratory abnormalities related to blinatumomab. A randomized trial is required in order to confirm clinical benefit.

FDA Approval: Blinatumomab